Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.

Recent clinical advances with chimeric antigen receptor (CAR) T cells have led to the accelerated clinical approval of CD19-CARs to treat acute lymphoblastic leukemia. The CAR T cell therapy is nevertheless associated with toxicities, especially if the CARs are not entirely tumor-specific. Therefore...

Full description

Saved in:
Bibliographic Details
Main Authors: Esther Drent, Renée Poels, Manon J Mulders, Niels W C J van de Donk, Maria Themeli, Henk M Lokhorst, Tuna Mutis
Format: Artigo
Language:Inglês
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5976165?pdf=render
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items